Compare Citius Pharmaceuticals Inc (CTXR) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Wipro Limited — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Wipro Limited trades at $1.86 (market cap $18.57B). The key difference: Wipro Limited is far larger — about 1268.4× Citius Pharmaceuticals Inc's market cap, and Wipro Limited pays a 10.42% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | WIT | |
|---|---|---|
Market Cap | $14.64M | $18.57B |
Sector | Health | Technology |
52-Week High | $1.82 | $3.06 |
52-Week Low | $0.53 | $1.82 |
Enterprise Value | $10.86M | $14.96B |
Dividend Yield | — | 10.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
WIT trades at $1.90, up 1.6% with bearish technical signals despite recent AI partnership announcements. The company shows mixed fundamentals with declining revenue from $904.9B in 2023 to $890.9B in 2025, though net income improved to $131.4B with a 14.74% margin. Recent earnings misses and weak guidance have tempered investor enthusiasm despite strong cash flow generation and AI initiatives.
WIT presents a cautious outlook with analyst consensus leaning bearish (19% buy vs 33% sell). While valuation appears reasonable (P/E 14.27) and AI partnerships offer growth potential, persistent revenue declines and execution risks in a competitive IT services market warrant careful monitoring. The stock faces near-term pressure from technical weakness and growth concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
